Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232

Reporter: J. Nicholas Lukens, MD
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 5 de junio del 2011

Translation for this article does not exist


Where Are the Adults in the Room?
by Rodney Warner, JD
November 20, 2015

Related News

Nelarabine Plus Chemo Viable in Children With T-Cell ALL

Jul 2, 2012

Nelarabine well tolerated; encouraging for pediatric patients with slow early response in T-cell ALL

Pediatric High-Risk Leukemia Survival Has Improved Over Time

Jul 25, 2011

Improved AML/ALL outcomes following allogeneic, non-allogeneic hematopoietic cell transplantation

CT Scans Up Risk of Leukemia, Brain Tumors in Young

Jun 8, 2012

Relative risk from radiation increases risk about three-fold, although absolute risk is still small